OKYO Pharma CEO Gary Jacob Transitions To CDO; Appoints Robert Dempsey As CEO

January 05, 2026 — 07:25 am EST

Written by RTTNews.com for RTTNews

(RTTNews) - OKYO Pharma Ltd. (OKYO), on Monday, said it has appointed Robert Dempsey as Chief Executive Officer, effective immediately.

Robert Dempsey will take over from Gary Jacob, who has transitioned to the role of chief development officer and will continue to serve as a board member.

The company said Dempsey brings more than two decades of global ophthalmology experience spanning drug development, commercialization and strategic transactions.

Dempsey previously served as group vice president and head of global ophthalmology at Shire.

The company said the leadership change is intended to support the next phase of growth, with a focus on advancing its lead asset, urcosimod, for the treatment of neuropathic corneal pain and other ocular inflammatory diseases.

On Friday, OKYO Pharma closed trading 7.21% higher at $2.2300 on the Nasdaq.

RTTNews

Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

OKYO Pharma CEO Gary Jacob Transitions To CDO; Appoints Robert Dempsey As CEO

Tags

Latest Articles